Summary of preliminary data from randomized trials of darbepoetin
| Citation . | Treatment arms . | Blinding . | No. patients . | Outcomes assessed8-150 . |
|---|---|---|---|---|
| Kotasek et al34 | Placebo | Double | 24 | a,c |
| NESP 1 | 32 | |||
| NESP 2 | 17 | |||
| NESP 3 | 46 | |||
| Pirker et al35 | Placebo | Double | 158 | a,b,c,d |
| NESP 1 | 156 | |||
| Hedenus et al36 | Placebo | Unknown | 11 | a,c |
| NESP 1 | 11 | |||
| NESP 2 | 22 | |||
| NESP 3 | 22 | |||
| Glaspy et al37 | Epoetin (tiw) | Unknown | 53 | a,c,d |
| NESP (weekly) 5 doses | 216 | |||
| Epoetin (weekly) | 32 | |||
| NESP (q 2 wk) 4 doses | 126 | |||
| Kotasek et al38 | Placebo (q 3 wk) | Double | 51 | a,b,c |
| NESP (q 3 wk) 6 doses | 198 | |||
| Placebo (q 4 wk) | 31 | |||
| NESP (q 4 wk) 4 doses | 125 |
| Citation . | Treatment arms . | Blinding . | No. patients . | Outcomes assessed8-150 . |
|---|---|---|---|---|
| Kotasek et al34 | Placebo | Double | 24 | a,c |
| NESP 1 | 32 | |||
| NESP 2 | 17 | |||
| NESP 3 | 46 | |||
| Pirker et al35 | Placebo | Double | 158 | a,b,c,d |
| NESP 1 | 156 | |||
| Hedenus et al36 | Placebo | Unknown | 11 | a,c |
| NESP 1 | 11 | |||
| NESP 2 | 22 | |||
| NESP 3 | 22 | |||
| Glaspy et al37 | Epoetin (tiw) | Unknown | 53 | a,c,d |
| NESP (weekly) 5 doses | 216 | |||
| Epoetin (weekly) | 32 | |||
| NESP (q 2 wk) 4 doses | 126 | |||
| Kotasek et al38 | Placebo (q 3 wk) | Double | 51 | a,b,c |
| NESP (q 3 wk) 6 doses | 198 | |||
| Placebo (q 4 wk) | 31 | |||
| NESP (q 4 wk) 4 doses | 125 |
NESP indicates novel erythropoetin-stimulating protein; tiw, thrice weekly; and q, once every.
a indicates change in hemoglobin; b, transfusion requirements (number of units); c, proportion of patients transfused; and d, quality of life.